In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BridgeBio Pharma, Inc.

http://bridgebio.com/

Latest From BridgeBio Pharma, Inc.

Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities

A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.

Financing Growth

Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development

US FDA, Foundation for the NIH, and NCI are considering a new PPP aimed at creating a repeatable process for development of drugs to treat ultra-rare cancers where commercial viability is lacking. Stakeholders say industry incentives, IP issues and reimbursement need attention.

Rare Diseases Research & Development

BridgeBio ATTR-CM Data Ignite Discussion Around Financing, Partnerships

The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.

Clinical Trials Business Strategies

BridgeBio May See Quicker Market Entry For Muscular Dystrophy Drug

BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adrenas Therapeutics
    • Aspa Therapeutics
    • Audition Therapeutics
    • Calcilytix Therapeutics
    • CoA Therapeutics
    • Fortify Therapeutics
    • Origin Biosciences
    • Phoenix Tissue Repair, Inc.
    • QED Therapeutics
    • Retinagenix LLC
UsernamePublicRestriction

Register